Current research on pharmacologic and regenerative therapies for osteoarthritis

Wei Zhang, H. Ouyang, C.R. Dass, Jiake Xu

    Research output: Contribution to journalReview article

    87 Citations (Scopus)

    Abstract

    Osteoarthritis (OA) is a degenerative joint disorder commonly encountered in clinical practice, and is the leading cause of disability in elderly people. Due to the poor self-healing capacity of articular cartilage and lack of specific diagnostic biomarkers, OA is a challenging disease with limited treatment options. Traditional pharmacologic therapies such as acetaminophen, non-steroidal anti-inflammatory drugs, and opioids are effective in relieving pain but are incapable of reversing cartilage damage and are frequently associated with adverse events. Current research focuses on the development of new OA drugs (such as sprifermin/recombinant human fibroblast growth factor-18, tanezumab/monoclonal antibody against β-nerve growth factor), which aims for more effectiveness and less incidence of adverse effects than the traditional ones. Furthermore, regenerative therapies (such as autologous chondrocyte implantation (ACI), new generation of matrix-induced ACI, cell-free scaffolds, induced pluripotent stem cells (iPS cells or iPSCs), and endogenous cell homing) are also emerging as promising alternatives as they have potential to enhance cartilage repair, and ultimately restore healthy tissue. However, despite currently available therapies and research advances, there remain unmet medical needs in the treatment of OA. This review highlights current research progress on pharmacologic and regenerative therapies for OA including key advances and potential limitations.
    Original languageEnglish
    Article number15040
    Pages (from-to)1-14
    Number of pages14
    JournalBone Research
    Volume4
    DOIs
    Publication statusPublished - 1 Mar 2016

    Fingerprint

    Osteoarthritis
    Research
    Chondrocytes
    Cartilage
    Therapeutics
    Induced Pluripotent Stem Cells
    Articular Cartilage
    Nerve Growth Factor
    Acetaminophen
    Pharmaceutical Preparations
    Opioid Analgesics
    Anti-Inflammatory Agents
    Joints
    Biomarkers
    Monoclonal Antibodies
    Pain
    Incidence
    fibroblast growth factor 18

    Cite this

    Zhang, Wei ; Ouyang, H. ; Dass, C.R. ; Xu, Jiake. / Current research on pharmacologic and regenerative therapies for osteoarthritis. In: Bone Research. 2016 ; Vol. 4. pp. 1-14.
    @article{765732c5b89a4a70a74bafb3ce818290,
    title = "Current research on pharmacologic and regenerative therapies for osteoarthritis",
    abstract = "Osteoarthritis (OA) is a degenerative joint disorder commonly encountered in clinical practice, and is the leading cause of disability in elderly people. Due to the poor self-healing capacity of articular cartilage and lack of specific diagnostic biomarkers, OA is a challenging disease with limited treatment options. Traditional pharmacologic therapies such as acetaminophen, non-steroidal anti-inflammatory drugs, and opioids are effective in relieving pain but are incapable of reversing cartilage damage and are frequently associated with adverse events. Current research focuses on the development of new OA drugs (such as sprifermin/recombinant human fibroblast growth factor-18, tanezumab/monoclonal antibody against β-nerve growth factor), which aims for more effectiveness and less incidence of adverse effects than the traditional ones. Furthermore, regenerative therapies (such as autologous chondrocyte implantation (ACI), new generation of matrix-induced ACI, cell-free scaffolds, induced pluripotent stem cells (iPS cells or iPSCs), and endogenous cell homing) are also emerging as promising alternatives as they have potential to enhance cartilage repair, and ultimately restore healthy tissue. However, despite currently available therapies and research advances, there remain unmet medical needs in the treatment of OA. This review highlights current research progress on pharmacologic and regenerative therapies for OA including key advances and potential limitations.",
    author = "Wei Zhang and H. Ouyang and C.R. Dass and Jiake Xu",
    year = "2016",
    month = "3",
    day = "1",
    doi = "10.1038/boneres.2015.40",
    language = "English",
    volume = "4",
    pages = "1--14",
    journal = "Bone Research",
    issn = "2095-4166",
    publisher = "Nature Publishing Group - Macmillan Publishers",

    }

    Current research on pharmacologic and regenerative therapies for osteoarthritis. / Zhang, Wei; Ouyang, H.; Dass, C.R.; Xu, Jiake.

    In: Bone Research, Vol. 4, 15040 , 01.03.2016, p. 1-14.

    Research output: Contribution to journalReview article

    TY - JOUR

    T1 - Current research on pharmacologic and regenerative therapies for osteoarthritis

    AU - Zhang, Wei

    AU - Ouyang, H.

    AU - Dass, C.R.

    AU - Xu, Jiake

    PY - 2016/3/1

    Y1 - 2016/3/1

    N2 - Osteoarthritis (OA) is a degenerative joint disorder commonly encountered in clinical practice, and is the leading cause of disability in elderly people. Due to the poor self-healing capacity of articular cartilage and lack of specific diagnostic biomarkers, OA is a challenging disease with limited treatment options. Traditional pharmacologic therapies such as acetaminophen, non-steroidal anti-inflammatory drugs, and opioids are effective in relieving pain but are incapable of reversing cartilage damage and are frequently associated with adverse events. Current research focuses on the development of new OA drugs (such as sprifermin/recombinant human fibroblast growth factor-18, tanezumab/monoclonal antibody against β-nerve growth factor), which aims for more effectiveness and less incidence of adverse effects than the traditional ones. Furthermore, regenerative therapies (such as autologous chondrocyte implantation (ACI), new generation of matrix-induced ACI, cell-free scaffolds, induced pluripotent stem cells (iPS cells or iPSCs), and endogenous cell homing) are also emerging as promising alternatives as they have potential to enhance cartilage repair, and ultimately restore healthy tissue. However, despite currently available therapies and research advances, there remain unmet medical needs in the treatment of OA. This review highlights current research progress on pharmacologic and regenerative therapies for OA including key advances and potential limitations.

    AB - Osteoarthritis (OA) is a degenerative joint disorder commonly encountered in clinical practice, and is the leading cause of disability in elderly people. Due to the poor self-healing capacity of articular cartilage and lack of specific diagnostic biomarkers, OA is a challenging disease with limited treatment options. Traditional pharmacologic therapies such as acetaminophen, non-steroidal anti-inflammatory drugs, and opioids are effective in relieving pain but are incapable of reversing cartilage damage and are frequently associated with adverse events. Current research focuses on the development of new OA drugs (such as sprifermin/recombinant human fibroblast growth factor-18, tanezumab/monoclonal antibody against β-nerve growth factor), which aims for more effectiveness and less incidence of adverse effects than the traditional ones. Furthermore, regenerative therapies (such as autologous chondrocyte implantation (ACI), new generation of matrix-induced ACI, cell-free scaffolds, induced pluripotent stem cells (iPS cells or iPSCs), and endogenous cell homing) are also emerging as promising alternatives as they have potential to enhance cartilage repair, and ultimately restore healthy tissue. However, despite currently available therapies and research advances, there remain unmet medical needs in the treatment of OA. This review highlights current research progress on pharmacologic and regenerative therapies for OA including key advances and potential limitations.

    U2 - 10.1038/boneres.2015.40

    DO - 10.1038/boneres.2015.40

    M3 - Review article

    VL - 4

    SP - 1

    EP - 14

    JO - Bone Research

    JF - Bone Research

    SN - 2095-4166

    M1 - 15040

    ER -